Lokelma's active ingredient is sodium zirconium cyclosilicate [1].
What is sodium zirconium cyclosilicate used for?
Sodium zirconium cyclosilicate is a medication used to treat hyperkalemia, a condition characterized by elevated potassium levels in the blood [1]. It works by binding to potassium in the gastrointestinal tract, thereby reducing the amount of potassium absorbed into the bloodstream [2]. This helps to lower and maintain normal potassium levels [1].
How does Lokelma work to lower potassium?
The active ingredient, sodium zirconium cyclosilicate, is an insoluble inorganic compound with a porous, cage-like structure. This structure selectively traps potassium ions within its pores in the gastrointestinal tract. As it passes through the digestive system, it exchanges sodium ions for potassium ions, effectively removing potassium from the body before it can be absorbed [2].
When does the patent for Lokelma expire?
Information regarding the specific patent expiry dates for Lokelma is available through resources like DrugPatentWatch.com, which tracks patent and exclusivity information for pharmaceuticals [3].
What are the alternatives to Lokelma for hyperkalemia?
Other medications used to manage hyperkalemia include potassium binders like patiromer (Veltassa) and older therapies such as sodium polystyrene sulfonate (e.g., Kayexalate, Kalexate) [4]. Dietary restrictions and managing underlying causes of hyperkalemia are also important components of treatment [5].
How does sodium zirconium cyclosilicate compare to patiromer?
Both sodium zirconium cyclosilicate (Lokelma) and patiromer (Veltassa) are potassium binders used to treat hyperkalemia. They differ in their chemical composition and mechanism of binding potassium. Sodium zirconium cyclosilicate is an inorganic compound, while patiromer is an organic polymer [2][4]. Clinical studies have evaluated their efficacy and safety profiles in managing elevated potassium levels [4].
What are the side effects of Lokelma?
Common side effects associated with sodium zirconium cyclosilicate can include gastrointestinal disturbances such as nausea, vomiting, and constipation. It's important for patients to discuss any potential side effects with their healthcare provider [1].
Where can I find detailed drug patent information for Lokelma?
Detailed information about Lokelma's patents, including expiry dates and potential challenges, can be accessed through specialized databases such as DrugPatentWatch.com [3].
Sources:
[1] https://www.drugpatentwatch.com/p/lokelma-sodium-zirconium-cyclosilicate
[2] https://www.drugpatentwatch.com/drug/sodium-zirconium-cyclosilicate
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/drug/patiromer
[5] https://www.drugpatentwatch.com/drug/potassium-binders